Clinical trial NCT03190434: Pivotal Study of the AL-SENSE in Diagnosis Amniotic Fluid Leakage
Official title: Pivotal Study of the AL-SENSE in Diagnosis Amniotic Fluid Leakage
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: AMNIOTIC FLUID LEAKAGE
Lead sponsor: Common Sense
Sponsor class: OTHER
First posted: 2017-06-16
Enrollment: 340
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Pregnant women arriving at the hospital and reporting unidentified wetness

Brief summary: This study is designed to demonstrate that the performance of the AL-SENSE developed by Common Sense Ltd. is safe and effective and can be used to indicate if the patient may be experiencing an amniotic fluid leakage or a "water breaking". The AL-SENSE is an extended shelf-life product that is technically simple, fast to react, visually readable, and therefore enables women to test the cause of any unidentified wetness. An additional, secondary objective is to show that the AL-SENSE is associated with levels of sensitivity and specificity that are comparable to those specified for the currently marketed AMNIOTESTTM (nitrazine yellow swabs; PRO LAB Diagnostics) product.

Detailed description: Baseline/ Screening

Potential subjects may undergo the informed consent process in the outpatient clinic.

Subjects attending the labor and delivery unit of the hospital or emergency clinic and reporting unidentified wetness (undetermined whether this is amniotic fluid leakage or urinary incontinence) will be enrolled in this study. After informed consent is obtained, each subject will be given a single AL-SENSE to use up to 12 hours or until the perception of wetness. The clinician will explain the proper use and handling of the AL-SENSE and how to read the result. The participants will be provided with instructions for use and also directed to read the Instructions For Use (IFU) prior to applying the AL-SENSE pad.

Product Usage After usage, the subject will read and record any occurrence of color change of the AL-SENSE 10 minutes after the liner removal and to mark if it changes color to blue or to green or not on the designated form.. The used liner will be placed in a separate sealed envelope with the subject's ID and product name and protocol number on the outside.

The subjects will fill out the questionnaire regarding the product usage experience and the liner color reading with no help from the investigator, to validate IFU reading comprehension. The completed form will be placed in a sealed envelope with the subject's initials and study number on the outside.

Clinical Diagnosis A blinded clinician will perform a "standard clinical diagnosis" (clinical assessment), and record the results on a worksheet to be included in the case report form. The standard clinical diagnostic methods will include the following tests: (1) Pooling test, (2) Ferning test, (3) Nitrazine paper or pH paper test. A positive Pooling test and/or positive results in both the Nitrazine or pH test and the Ferning test will be defined as a positive clinical test result for amniotic fluid.

Although the preferred sequence is using the liner before clinical diagnosis, diagnostic procedures may be done before liner use, as long as lubricants are not used for procedures. The use of lubricants interferes with the accuracy of liner reaction to amniotic fluid.

If the liner is removed for clinical testing before sufficient fluid has collected, it may either be reused or a fresh liner may be dispensed. Note that any use of lubricants contraindicates further usage of Al-Sense.

The subject is expected to remain at the hospital for the duration of the test for completing the "standard clinical diagnosis" tests, required by the protocol.

A positive Pooling test or positive results in the other 2 tests is defined as a positive clinical assessment.

Although the performance of the AL-SENSE is examined in this study, subject treatment will be based only on the standard hospital diagnostic methods.

Eligibility criteria: Inclusion Criteria:

* Age 18 years and 45 years.
* Subject minimum 16 weeks of pregnancy.
* Who will sign the informed consent form.
* Who arrive at the obstetric department reporting a feeling of vaginal wetness feeling undetermined whether this is amniotic fluid leakage or urinary incontinence).

Exclusion Criteria:

* Subject who has experienced intermittent vaginal bleeding between the 2nd and 3rd trimester.
* Subjects that have had sexual relations within the last 12 hours.
* Subject is unable or unwilling to cooperate with study procedures.
* Subject used the AL-SENSE before joining this study.
* Subject that has been diagnosed with Bacterial Vaginosis or Trichomonas infection within the last 3 days.
* Subject using vaginal products such as some douching formulas, some antibiotic treatments which reduce lactobacillus population.

Primary outcomes:
measure: amniotic fluid leakage
timeFrame: day 1
Secondary outcomes:
measure: result reading clarity
timeFrame: day 1
Other outcomes:
Locations:
Study officials:
affiliation: Ottawa Hospital Research Institute
name: Amanda Black, MD
role: PRINCIPAL_INVESTIGATOR
References: